ExesaLibero Pharma

The company is working on a new approach to treating bone erosion based on a common pathway in the cell that infiltrates bone and joints. The primary mission ExesaLibero Pharma, Inc is to complete the vital preclinical toxicology and efficacy studies for a groundbreaking small-molecule drug. This extraordinary innovation holds the key to controlling the insidious bone erosion that plagues numerous debilitating diseases, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis. By tackling this critical issue head-on, we aim to enhance the lives of countless individuals afflicted by these disease conditions. The results of these studies will form the bases for an Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, we expect to initiate clinical trials that will lead to full approval of the drug for clinical use.